Department of Clinical Biochemistry, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland.
Centre for Diabetes, Endocrinology and Metabolism, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland.
Clin Chem Lab Med. 2019 Mar 26;57(4):510-520. doi: 10.1515/cclm-2018-0534.
Growth differentiation factor-15 (GDF-15), a stress responsive cytokine, is a promising biomarker of renal functional decline in diabetic kidney disease (DKD). This study aimed primarily to establish normative data and secondarily to evaluate the potential utility of GDF-15 in DKD using Roche Diagnostics electrochemiluminescence immunoassay (ECLIA) in an Irish Caucasian population.
Following informed consent, 188 healthy volunteers and 128 participants with diabetes (72 with and 56 without DKD) were recruited to a cross-sectional study. Baseline demographics, anthropometric measurements and laboratory measurements were recorded. Blood for GDF-15 measurement was collected into plain specimen tubes kept at room temperature and processed (centrifugation, separation of serum, freezing at -80 °C) within 1 h of phlebotomy pending batch analyses. Reference intervals were determined using the 2.5th and 97.5th percentiles for serum GDF-15 concentration.
Of 188 healthy participants, 63 failed to meet study inclusion criteria. The reference interval for serum GDF-15 was 399 ng/L (90% confidence interval [CI]: 399-399) - 1335 ng/L (90% CI: 1152-1445). Receiver operator characteristics (ROC) curve analysis for DKD determined the area under the ROC curve to be 0.931 (95% CI: 0.893-0.959; p<0.001). The optimum GDF-15 cutoff for predicting DKD was >1136 ng/L providing a diagnostic sensitivity and specificity of 94.4% and 79%, respectively, and positive likelihood ratio of 4.5:1 (95% CI: 3.4-6.0).
The reference interval for serum GDF-15 in a healthy Irish Caucasian population using Roche Diagnostics ECLIA was established and a preliminary determination of the potential of GDF-15 as a screening test for DKD was made. Further prospective validation with a larger DKD cohort will be required before the cutoff presented here is recommended for clinical use.
生长分化因子 15(GDF-15)是一种应激反应细胞因子,是糖尿病肾病(DKD)肾功能下降的有前途的生物标志物。本研究旨在首先建立规范数据,其次使用罗氏诊断电化学发光免疫分析(ECLIA)在爱尔兰白种人群中评估 GDF-15 在 DKD 中的潜在应用。
在获得知情同意后,招募了 188 名健康志愿者和 128 名糖尿病患者(72 名伴 DKD 和 56 名无 DKD)进行横断面研究。记录基线人口统计学、人体测量学和实验室测量值。采集用于 GDF-15 测量的血液,置于室温下的普通标本管中,并在采血后 1 小时内进行处理(离心、血清分离、-80°C 冷冻),以备批分析。使用血清 GDF-15 浓度的第 2.5 和 97.5 百分位数确定血清 GDF-15 浓度的参考区间。
在 188 名健康参与者中,有 63 名不符合研究纳入标准。血清 GDF-15 的参考区间为 399ng/L(90%CI:399-399)-1335ng/L(90%CI:1152-1445)。用于 DKD 的接收器操作特性(ROC)曲线分析确定 ROC 曲线下面积为 0.931(95%CI:0.893-0.959;p<0.001)。预测 DKD 的最佳 GDF-15 截断值>1136ng/L,提供 94.4%的诊断敏感性和 79%的特异性,阳性似然比为 4.5:1(95%CI:3.4-6.0)。
使用罗氏诊断 ECLIA 建立了健康爱尔兰白种人群血清 GDF-15 的参考区间,并初步确定了 GDF-15 作为 DKD 筛查试验的潜力。需要进一步对更大的 DKD 队列进行前瞻性验证,然后才能推荐本文提出的截断值用于临床使用。